- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04038619
Transplantation de microbiote fécal dans le traitement de la diarrhée ou de la colite induite par un inhibiteur de point de contrôle immunitaire chez les patients atteints d'un cancer génito-urinaire
Transplantation de microbiote fécal (FMT) pour la diarrhée/colite induite par un inhibiteur de point de contrôle immunitaire chez les patients atteints d'un cancer génito-urinaire
This trial studies how well fecal microbiota transplantation works in treating diarrhea or colitis (inflammation of the intestines) that is caused by certain types of medications (called immune-checkpoint inhibitors) in patients with genitourinary cancer. Fecal microbiota transplantation may effectively reduce the incidence of immune checkpoint inhibitor-induced diarrhea/colitis.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
PRIMARY OBJECTIVES:
- To assess the safety and tolerability of fecal microbiota transplantation (FMT).
- To assess the efficacy of FMT for clinical remission/response of immune-related diarrhea/colitis.
SECONDARY OBJECTIVES:
- To measure the recurrence rate after achieving clinical remission/response of immune-related diarrhea/colitis.
EXPLORATORY OBJECTIVES:
- To assess the efficacy of FMT to achieve endoscopic remission of immune-related diarrhea/colitis.
- To assess the efficacy of FMT to achieve histological remission of immune-related diarrhea/colitis.
- To assess the efficacy of FMT on recurrence of immune-related diarrhea/colitis after resumption of immune checkpoint inhibitors (ICPI).
- To assess immunological, molecular and microbiome changes in tissue/blood/stool.
To study the efficacy and/ or benefit of PuraStat gel in the healing of mucosal ulcers and its hemostatic effect on bleeding lesions
OUTLINE:
Patients receive loperamide orally (PO). After 4 hours, patients undergo FMT via colonoscopy over 15-30 minutes.
After completion of study treatment, patients are followed up at 2, 4, and 8 weeks, and then at 3 months.
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Yinghong Wang
- Numéro de téléphone: 281-221-9138
- E-mail: ywang59@mdanderson.org
Lieux d'étude
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- Recrutement
- M D Anderson Cancer Center
-
Chercheur principal:
- Yinghong Wang
-
Contact:
- Yinghong Wang
- Numéro de téléphone: 713-792-7672
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Diagnosis of any type of genitourinary (kidney, bladder and prostate), melanoma, non-melanoma skin cancer, lung, head & neck, sarcoma/lymphoma, gastrointestinal system (luminal GI, hepatobiliary, pancreas), gynecology system (ovarian, uterine, cervical), and breast malignancies
- Treatment with any ICPI agent(s)
- Participants with new onset of ≥ grade 2 ICPI-induced diarrhea and/or colitis symptoms based on the Common Terminology Criteria for Adverse Events (CTCAE) version 5 within 45 days prior to date of FMT treatment without involvement of non- GI toxicity
- Participants with a history of steroid use before FMT can be allowed if last dose was > 30 days prior to FMT treatment or treatment duration was for <7 days beyond one week prior to FMT treatment
- Participants with a history of immunosuppressant (Infliximab, Vedolizumab etc) use before FMT can be allowed if last dose was administered ≥ 3 months prior to FMT treatment when used for the treatment of conditions other than for ICI- induced GI toxicities (e.g., Infliximab is used in the treatment of Crohn's disease, rheumatoid arthritis, plaque psoriasis, and Vedolizumab is used in treating ulcerative colitis)
- No concern for active concomitant GI infection at the time of initiation of protocol therapy as confirmed by stool tests or as per the treating physician based on clinical presentation
- Patient has been cleared for enrollment by Infectious Diseases consultant or treating physician if positive infection workup or screening tests (e.g., lifelong positive T-spot due to BCG inoculation, chronic colonization) prior to initiation of protocol therapy and/ or imaging (e.g. CXR, CT CAP etc) confirms the absence of active infections (e.g. TB) within 60 days prior to initiation of protocol therapy
- Ability to understand and willingness to sign an informed consent form
- Life expectancy > 6 months
Exclusion Criteria
- Age younger than 18 years
- Participants with persistent GI infection confirmed with positive stool test(s) despite completing 5 days of antibiotics prior to initiation of protocol therapy
- History of inflammatory bowel disease, and/or radiation enteritis or colitis with active disease status at the time of study treatment initiation
- Pregnant and breastfeeding women
- Women who have positive urine or serum pregnancy test or refuse to do pregnancy test unless last menstrual cycle was > 1 year prior to consent and/ or clear documentation states that participant is peri- or post-menopausal or there has been recent supporting objective evidence of 'no pregnancy' status (e.g. blood or imaging) within 30 days prior to date of study treatment
- Immunosuppressive treatment at onset of ICPI-induced diarrhea/colitis
- Any medical conditions (e.g. severe heart failure, brain hemorrhage, septic shock, etc.) that are high risk for colonoscopy procedure by the assessment of the study PI or Co-PIs.
- Participants who develop concurrent non-GI toxicity at the time of study treatment
- Donors at risk for monkeypox infection and/ or exposure as determined by a questionnaire
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Treatment (loperamide, colonoscopy, FMT)
Patients receive loperamide PO. After 4 hours, patients undergo FMT via colonoscopy over 15-30 minutes. |
Undergo FMT via colonoscopy
Autres noms:
Given PO |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of fecal microbiota transplantation (FMT)-related adverse events
Délai: Up to 3 months post-FMT
|
Assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5. All events are recorded with grade and attribution to FMT. |
Up to 3 months post-FMT
|
|
Clinical response/remission of immune-related diarrhea/colitis
Délai: At 2 weeks post-FMT
|
Clinical remission of immune related events defined as improvement of symptoms of grade 1 or lower within 2 weeks post-FMT. Clinical partial response of immune related diarrhea/colitis defined as improvement of diarrhea/colitis to a lower grade than the initial presentation but not meeting criteria of clinical remission at 2 week post-FMT time point. |
At 2 weeks post-FMT
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Recurrent immune-related diarrhea/colitis within 3 months post-FMT after initially achieving clinical remission/response
Délai: Up to 3 months post-FMT
|
Recurrent immune-related diarrhea colitis events occurring post-FMT are recorded throughout the follow-up period. |
Up to 3 months post-FMT
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Endoscopic remission (Mayo Clinic sub-score 0-1) of immune-related diarrhea/colitis
Délai: At 4 weeks and 8 weeks post-FMT
|
Endoscopic remission is defined as Mayo Clinic endoscopic subscore 0 or 1 (absence of ulcers, with or without mild erythema, friability and decreased vascular pattern). |
At 4 weeks and 8 weeks post-FMT
|
|
Histological remission (resolution of active inflammation) of immune-related diarrhea/colitis
Délai: At 8 weeks post-FMT
|
Histological remission is defined resolution of active inflammation on biopsy sample. |
At 8 weeks post-FMT
|
|
Recurrent immune-related diarrhea/colitis following FMT and immune checkpoint inhibitors (ICPI) resumption within 6 months of ICPI resumption
Délai: Up to 6 months after restarting ICPI
|
Recurrent immune-related diarrhea colitis events occurring post-FMT will be recorded throughout the follow-up period. |
Up to 6 months after restarting ICPI
|
|
Measure immunological measures (including levels of cytokines (IL-6, 17, TNF, etc.) in tissue/blood/stool samples
Délai: Up to 3 months
|
Blood, stool, and colon tissues will be collected from at each scheduled time point. Markers of interest for immunological and biological profiles include levels of cytokines (IL-6, 17, TNF, etc). Special attention will focus on Bacteroidetes, Akkermansia, and Blautia. |
Up to 3 months
|
|
Frequencies of immune cells (CD4/8 T cells, regulatory T cells [Treg], macrophages, etc.) in tissue/blood/stool samples
Délai: Up to 3 months
|
Blood, stool, and colon tissues will be collected from at each scheduled time point. Markers of interest for immunological and biological profiles include frequencies of immune cells (CD4/8 T cells, Treg, macrophages, etc). Special attention will focus on Bacteroidetes, Akkermansia, and Blautia. |
Up to 3 months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Yinghong Wang, M.D. Anderson Cancer Center
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies génitales
- Maladies du système endocrinien
- Tumeurs par site
- Tumeurs
- Maladies urogénitales masculines
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Signes et symptômes digestifs
- Maladies intestinales
- Maladies des voies respiratoires
- Tumeurs par type histologique
- Maladies du système digestif
- Maladies gastro-intestinales
- Maladies utérines
- Maladies génitales, femme
- Maladies pulmonaires
- Tumeurs des glandes endocrines
- Tumeurs des voies respiratoires
- Tumeurs thoraciques
- Maladies du côlon
- Maladies ovariennes
- Maladies annexielles
- Tumeurs génitales, femme
- Troubles gonadiques
- Maladies de la peau
- Gastro-entérite
- Maladies du sein
- Maladies du col de l'utérus
- Tumeurs neuroectodermiques
- Tumeurs, cellules germinales et embryonnaires
- Tumeurs, tissu nerveux
- Tumeurs neuroendocrines
- Nevi et mélanomes
- Tumeurs cutanées
- Conditions pathologiques, signes et symptômes
- Maladies de la peau et du tissu conjonctif
- Signes et symptômes
- Tumeurs pulmonaires
- Tumeurs ovariennes
- Colite
- Tumeurs mammaires
- Tumeurs du col de l'utérus
- Mélanome
- Tumeurs urogénitales
- Tumeurs utérines
- Diarrhée
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Thérapeutique
- Pipéridines
- Thérapie biologique
- Lopéramide
- Transplantation de microbiote fécal
Autres numéros d'identification d'étude
- 2018-0663
- 2018-0663 (Autre identifiant: M D Anderson Cancer Center)
- NCI-2019-02660 (Identificateur de registre: CTRP (Clinical Trial Reporting Program))
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .